milrinone has been researched along with Abnormality, Heart in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two authors searched MEDLINE, PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, the Cochrane Library, Wanfang database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI) for randomized controlled trials (RCTs) about the application of milrinone in the treatment of heart failure caused by severe pneumonia in children with CHD in children up to December 10, 2022." | 9.41 | Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis. ( Cai, L; Diao, S; Shao, W; Zhou, L, 2023) |
| "Levosimendan compared with milrinone did not reduce the occurrence rate of acute kidney injury in infants after total corrective heart surgery for atrioventricular septal defect, ventricular septal defect, or Tetralogy of Fallot." | 9.30 | The Effect of Levosimendan Versus Milrinone on the Occurrence Rate of Acute Kidney Injury Following Congenital Heart Surgery in Infants: A Randomized Clinical Trial. ( Castellheim, A; Keski-Nisula, J; Ricksten, SE; Romlin, BS; Suominen, PK; Synnergren, M; Thorlacius, EM; Vistnes, M; Wåhlander, H, 2019) |
| "There is insufficient evidence of the effectiveness of prophylactic milrinone in preventing death or low cardiac output syndrome in children undergoing surgery for congenital heart disease, compared to placebo." | 8.91 | Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. ( Burkhardt, BE; Rücker, G; Stiller, B, 2015) |
| "Two authors searched MEDLINE, PubMed, Embase, Science Direct, Cochrane Central Register of Controlled Trials, the Cochrane Library, Wanfang database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI) for randomized controlled trials (RCTs) about the application of milrinone in the treatment of heart failure caused by severe pneumonia in children with CHD in children up to December 10, 2022." | 5.41 | Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis. ( Cai, L; Diao, S; Shao, W; Zhou, L, 2023) |
| "The overall arrhythmia incidence was 50%, most commonly monomorphic ventricular tachycardia (n = 85, 12%), junctional ectopic tachycardia (n = 69, 10%), accelerated junctional rhythm (n = 58, 8%), and atrial tachyarrhythmias (including atrial fibrillation, atrial flutter, and ectopic or chaotic atrial tachycardia, n = 58, 8%)." | 5.37 | Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. ( Borgman, KY; Fish, FA; Kannankeril, PJ; Owen, J; Smith, AH, 2011) |
| "Levosimendan compared with milrinone did not reduce the occurrence rate of acute kidney injury in infants after total corrective heart surgery for atrioventricular septal defect, ventricular septal defect, or Tetralogy of Fallot." | 5.30 | The Effect of Levosimendan Versus Milrinone on the Occurrence Rate of Acute Kidney Injury Following Congenital Heart Surgery in Infants: A Randomized Clinical Trial. ( Castellheim, A; Keski-Nisula, J; Ricksten, SE; Romlin, BS; Suominen, PK; Synnergren, M; Thorlacius, EM; Vistnes, M; Wåhlander, H, 2019) |
| "There is insufficient evidence of the effectiveness of prophylactic milrinone in preventing death or low cardiac output syndrome in children undergoing surgery for congenital heart disease, compared to placebo." | 4.91 | Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. ( Burkhardt, BE; Rücker, G; Stiller, B, 2015) |
| "To prevent low cardiac output syndrome, prophylactic administration of milrinone after cardiopulmonary bypass is commonly used in small children." | 2.77 | Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study. ( Freynschlag, R; Gombotz, H; Hofer, A; Lechner, E; Leitner-Peneder, G; Mair, R; Rehak, P; Weinzettel, R, 2012) |
| "Milrinone was intravenously administered in three stages: a) baseline stage, in which patients had a stable hemodynamic status, ventilation and gas exchange, hemostasis, and body temperature; b) loading stage, in which a 50 microgram/kg intravenous loading dose of milrinone was administered over 15 mins; and c) infusion stage, in which milrinone was continuously infused at 0." | 2.68 | Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. ( Atz, AM; Burke, RP; Chang, AC; Wernovsky, G; Wessel, DL, 1995) |
| "In non-hyperdynamic septic shock, CI, SVI, and DO₂ significantly increased while SVRI significantly decreased after milrinone when compared to placebo." | 2.47 | The role of milrinone in children with cardiovascular compromise: review of the literature. ( Abdul-Khaliq, H; Brown, K; Gortner, L; Meyer, S, 2011) |
| "Milrinone is a phosphodiesterase type 3 inhibitor that results in a positive inotropic effect in the heart through an increase in cyclic adenosine monophosphate." | 1.62 | Circulating cyclic adenosine monophosphate concentrations in milrinone treated paediatric patients after congenital heart surgery. ( Campbell, K; Gist, KM; Karimpour-Fard, A; Korst, A; Miyamoto, SD; Nakano, SJ; Stauffer, BL; Sucharov, CC; Wempe, MF; Zhou, W, 2021) |
| "Milrinone is an inodilator widely used in the postoperative management of children undergoing cardiac surgery." | 1.56 | Milrinone Acts as a Vasodilator But Not an Inotrope in Children After Cardiac Surgery-Insights From Wave Intensity Analysis. ( Butt, W; Jones, B; Kowalski, R; Kwok, SY; Matha, S; Millar, J; Mynard, JP; Rahiman, S; Smolich, JJ, 2020) |
| " We employed a hierarchical framework by representing discrete probability models with continuous latent variables that depended on the dosage of drugs for a particular patient." | 1.48 | An Empirically Derived Pediatric Cardiac Inotrope Score Associated With Pediatric Heart Surgery. ( Chakraborty, A; Gossett, JM; Gupta, P; Imamura, M; Rettiganti, M; Vuong-Dac, MA; Wilcox, A, 2018) |
| " Further investigation of milrinone dosing recommendations may improve the postoperative outcomes of children." | 1.39 | Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease. ( Garcia Guerra, G; Joffe, AR; Kutsogiannis, DJ; Parshuram, CS; Senthilselvan, A, 2013) |
| "The overall arrhythmia incidence was 50%, most commonly monomorphic ventricular tachycardia (n = 85, 12%), junctional ectopic tachycardia (n = 69, 10%), accelerated junctional rhythm (n = 58, 8%), and atrial tachyarrhythmias (including atrial fibrillation, atrial flutter, and ectopic or chaotic atrial tachycardia, n = 58, 8%)." | 1.37 | Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias. ( Borgman, KY; Fish, FA; Kannankeril, PJ; Owen, J; Smith, AH, 2011) |
| "Amrinone was continuously infused at 10 micrograms/kg/min in 5 patients (Group A), or milrinone was continuously infused at 0." | 1.30 | [Hemodynamic effects of amrinone or milrinone in infant after right heart bypass operation]. ( Fuijmoto, J; Fuijwara, T; Ka, H; Kaneko, Y; Kanemoto, S; Kobayashi, J; Nagata, N; Okabe, H, 1998) |
| "Milrinone has been shown to increase cardiac output in children after cardiac surgery, but pharmacokinetic analysis has not been used to identify effective dose regimens." | 1.30 | The pharmacokinetics of milrinone in pediatric patients after cardiac surgery. ( Bailey, JM; Kanter, KR; Lu, W; Miller, BE; Tam, VK; Tosone, SR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (18.75) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 16 (50.00) | 24.3611 |
| 2020's | 5 (15.63) | 2.80 |
| Authors | Studies |
|---|---|
| Shao, W | 1 |
| Diao, S | 1 |
| Zhou, L | 1 |
| Cai, L | 1 |
| Rodríguez-Fanjul, J | 1 |
| Bobillo-Pérez, S | 1 |
| Girona-Alarcón, M | 1 |
| Sánchez-de-Toledo, J | 1 |
| Alexander, PMA | 1 |
| Akcan-Arikan, A | 1 |
| Shekerdemian, LS | 1 |
| Rahiman, S | 1 |
| Kowalski, R | 1 |
| Kwok, SY | 1 |
| Matha, S | 1 |
| Jones, B | 1 |
| Smolich, JJ | 1 |
| Mynard, JP | 1 |
| Butt, W | 1 |
| Millar, J | 1 |
| Gist, KM | 1 |
| Korst, A | 1 |
| Nakano, SJ | 1 |
| Stauffer, BL | 1 |
| Karimpour-Fard, A | 1 |
| Zhou, W | 1 |
| Campbell, K | 1 |
| Wempe, MF | 1 |
| Sucharov, CC | 1 |
| Miyamoto, SD | 1 |
| Gupta, P | 1 |
| Rettiganti, M | 1 |
| Wilcox, A | 1 |
| Vuong-Dac, MA | 1 |
| Gossett, JM | 1 |
| Imamura, M | 1 |
| Chakraborty, A | 1 |
| Cavigelli-Brunner, A | 1 |
| Hug, MI | 1 |
| Dave, H | 1 |
| Baenziger, O | 1 |
| Buerki, C | 1 |
| Bettex, D | 1 |
| Cannizzaro, V | 1 |
| Balmer, C | 1 |
| Dempsey, E | 1 |
| Rabe, H | 1 |
| Thorlacius, EM | 1 |
| Suominen, PK | 1 |
| Wåhlander, H | 1 |
| Keski-Nisula, J | 1 |
| Vistnes, M | 1 |
| Ricksten, SE | 1 |
| Synnergren, M | 1 |
| Romlin, BS | 1 |
| Castellheim, A | 1 |
| Kim-Campbell, N | 1 |
| Gretchen, C | 1 |
| Ritov, VB | 1 |
| Kochanek, PM | 1 |
| Balasubramani, GK | 1 |
| Kenny, E | 1 |
| Sharma, M | 1 |
| Viegas, M | 1 |
| Callaway, C | 1 |
| Kagan, VE | 1 |
| Bayír, H | 1 |
| Garcia Guerra, G | 1 |
| Joffe, AR | 1 |
| Senthilselvan, A | 1 |
| Kutsogiannis, DJ | 1 |
| Parshuram, CS | 1 |
| Linder, J | 1 |
| Dawson, E | 1 |
| Williams, P | 1 |
| Costello, JM | 1 |
| Dunbar-Masterson, C | 1 |
| Allan, CK | 1 |
| Gauvreau, K | 1 |
| Newburger, JW | 1 |
| McGowan, FX | 1 |
| Wessel, DL | 4 |
| Mayer, JE | 1 |
| Salvin, JW | 1 |
| Dionne, RE | 1 |
| Laussen, PC | 1 |
| Burkhardt, BE | 1 |
| Rücker, G | 1 |
| Stiller, B | 1 |
| Bianchi, MO | 1 |
| Cheung, PY | 1 |
| Phillipos, E | 1 |
| Aranha-Netto, A | 1 |
| Joynt, C | 1 |
| Singh, R | 1 |
| Choudhury, M | 1 |
| Saxena, A | 1 |
| Kapoor, PM | 1 |
| Juneja, R | 1 |
| Kiran, U | 1 |
| Cuevas Valenzuela, P | 1 |
| Rufino Ruiz, J | 1 |
| Palacios Blanco, E | 1 |
| Momeni, M | 1 |
| Rubay, J | 1 |
| Matta, A | 1 |
| Rennotte, MT | 1 |
| Veyckemans, F | 1 |
| Poncelet, AJ | 1 |
| Clement de Clety, S | 1 |
| Anslot, C | 1 |
| Joomye, R | 1 |
| Detaille, T | 1 |
| Meyer, S | 1 |
| Gortner, L | 1 |
| Brown, K | 1 |
| Abdul-Khaliq, H | 1 |
| Smith, AH | 1 |
| Owen, J | 1 |
| Borgman, KY | 1 |
| Fish, FA | 1 |
| Kannankeril, PJ | 1 |
| Lechner, E | 1 |
| Hofer, A | 1 |
| Leitner-Peneder, G | 1 |
| Freynschlag, R | 1 |
| Mair, R | 1 |
| Weinzettel, R | 1 |
| Rehak, P | 1 |
| Gombotz, H | 1 |
| Hoffman, TM | 3 |
| Bush, DM | 1 |
| Wernovsky, G | 4 |
| Cohen, MI | 1 |
| Wieand, TS | 1 |
| Gaynor, JW | 1 |
| Spray, TL | 3 |
| Rhodes, LA | 1 |
| Atz, AM | 3 |
| Kulik, TJ | 2 |
| Nelson, DP | 2 |
| Chang, AC | 3 |
| Bailey, JM | 3 |
| Akbary, A | 2 |
| Kocsis, JF | 2 |
| Kaczmarek, R | 1 |
| Khazin, V | 1 |
| Kaufman, Y | 1 |
| Zabeeda, D | 1 |
| Medalion, B | 1 |
| Sasson, L | 1 |
| Schachner, A | 1 |
| Ezri, T | 1 |
| Berry, JG | 1 |
| Askovich, B | 1 |
| Shaddy, RE | 1 |
| Hawkins, JA | 1 |
| Cowley, CG | 1 |
| Burke, RP | 1 |
| Pridjian, AK | 1 |
| Frohlich, ED | 1 |
| VanMeter, CH | 1 |
| McFadden, PM | 1 |
| Ochsner, JL | 1 |
| McBride, WT | 1 |
| McMurray, TJ | 1 |
| Nemoto, S | 1 |
| Sakai, A | 1 |
| Nakamura, K | 1 |
| Miyoshi, Y | 1 |
| Yasuhara, K | 1 |
| Okabe, H | 1 |
| Kaneko, Y | 1 |
| Nagata, N | 1 |
| Kobayashi, J | 1 |
| Kanemoto, S | 1 |
| Ka, H | 1 |
| Fuijmoto, J | 1 |
| Fuijwara, T | 1 |
| Miller, BE | 1 |
| Lu, W | 1 |
| Tosone, SR | 1 |
| Kanter, KR | 1 |
| Tam, VK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hemodynamic Effects of Dopamine Versus Norepinephrine Under General Anesthesia in Infant With Congenital Heart Disease[NCT04536194] | Phase 3 | 60 participants (Actual) | Interventional | 2020-10-10 | Completed | ||
| Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT00543309] | Phase 2 | 106 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to DSMB recommended termination based on interim outcomes analysis) | ||
| Multicenter Study for the Prevention of Post-Operative Cardiac Arrhythmias[NCT04234906] | Phase 4 | 870 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | ||
| STeroids to REduce Systemic Inflammation After Infant Heart Surgery (STRESS)[NCT03229538] | Phase 3 | 1,263 participants (Actual) | Interventional | 2017-10-18 | Completed | ||
| Phase 2 Prospective, Randomized, Double-Blind Pilot Study on Cardiac Output Following Corrective Open Heart Surgery in Children Less Than One Year: Use of Levosimendan Versus Milrinone.[NCT00549107] | Phase 2 | 40 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass[NCT00934843] | 77 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation[NCT02519335] | Phase 1 | 12 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to PI no longer at this facility) | ||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery[NCT04997291] | Phase 1 | 12 participants (Anticipated) | Interventional | 2021-04-09 | Recruiting | ||
| Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children[NCT02728128] | 53 participants (Actual) | Observational | 2016-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
arrhythmia lasting >30 seconds or requiring treatment (NCT00543309)
Timeframe: Postoperative day (POD) #0 through 5
| Intervention | Participants (Count of Participants) |
|---|---|
| I- Nesiritide | 16 |
| II- Milrinone | 21 |
| III- Placebo | 13 |
Cardiac index measured using Fick principle with measured oxygen consumption. (NCT00543309)
Timeframe: Postoperative hour #1
| Intervention | L/min/m2 (Median) |
|---|---|
| I- Nesiritide | 3.5 |
| II- Milrinone | 2.8 |
| III- Placebo | 2.5 |
Cardiac index measured using Fick principle with measured oxygen consumption. (NCT00543309)
Timeframe: Postoperative hour #8
| Intervention | L/min/m2 (Median) |
|---|---|
| I- Nesiritide | 3.2 |
| II- Milrinone | 2.9 |
| III- Placebo | 2.5 |
"Peak Inotrope Score = Doses of dopamine in mcg/kg/minute + dobutamine in mcg/kg/minute + (epinephrine in mcg/kg/minute x 100).~The lowest (best) possible Peak Inotrope Score = 0 dose equivalents. There is no maximum Peak Inotrope Score." (NCT00543309)
Timeframe: Initial 24 hours in CICU
| Intervention | dose equivalents (Median) |
|---|---|
| I- Nesiritide | 5 |
| II- Milrinone | 5 |
| III- Placebo | 5 |
(NCT00543309)
Timeframe: Initial 24 hours in CICU
| Intervention | mEq/liter (Median) |
|---|---|
| I- Nesiritide | 2.6 |
| II- Milrinone | 3.1 |
| III- Placebo | 3.1 |
(NCT00543309)
Timeframe: 30 days
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 20 |
| II- Milrinone | 18 |
| III- Placebo | 20 |
(NCT00543309)
Timeframe: 14 days after surgery
| Intervention | mg/dL (Median) |
|---|---|
| I- Nesiritide | 0.1 |
| II- Milrinone | 0.2 |
| III- Placebo | 0.2 |
Volume of urine in mL/kg per day (NCT00543309)
Timeframe: first 24 hours CICU admit
| Intervention | mL/kg per day (Median) |
|---|---|
| I- Nesiritide | 43 |
| II- Milrinone | 37 |
| III- Placebo | 34 |
Days during which one or more chest tubes were in place following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until final chest tube removed, assessed during postoperative hospitalization, up to 90 days.
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 5 |
| II- Milrinone | 5 |
| III- Placebo | 5 |
Days the patient was alive and out of hospital within the 180 days after Fontan surgery (NCT00543309)
Timeframe: 180 days
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 167 |
| II- Milrinone | 168 |
| III- Placebo | 170 |
Days of initial postoperative CICU care following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until initial discharge from the CICU, assessed during the postoperative hospitalization, up to 90 days.
| Intervention | days (Median) |
|---|---|
| I- Nesiritide | 3 |
| II- Milrinone | 3 |
| III- Placebo | 2 |
Hours of mechanical ventilation until initial extubation following the Fontan operation. (NCT00543309)
Timeframe: From Fontan operation until initial extubation, assessed during initial CICU stay, up to 30 days.
| Intervention | hours (Median) |
|---|---|
| I- Nesiritide | 24 |
| II- Milrinone | 23 |
| III- Placebo | 22 |
Plasma epinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 0 | 1.2 | 0.5 | 0.2 |
| II- Milrinone | 0 | 2.7 | 0.5 | 1.5 |
| III- Placebo | 0 | 2.1 | 1.0 | 1.3 |
N-terminal pro-brain natriuretic peptide levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | fmol/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 77 | 81 | 91 | 142 |
| II- Milrinone | 77 | 61 | 71 | 136 |
| III- Placebo | 88 | 77 | 88 | 109 |
Plasma norepinephrine levels measured at preoperative baseline and postoperative CICU hour 1, 8, 24. (NCT00543309)
Timeframe: Preoperative baseline to 24 hours after CICU admission
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| Preoperative baseline | 1 hour after CICU admit | 8 hours after CICU admit | 24 hours after CICU admit | |
| I- Nesiritide | 0.2 | 2.0 | 2.3 | 1.3 |
| II- Milrinone | 0.4 | 2.1 | 2.4 | 1.5 |
| III- Placebo | 0.5 | 2.9 | 1.3 | 1.3 |
Calculated as discharge date minus surgery date. (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 18 |
| Placebo Arm | 29 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 237 |
| Placebo Arm | 264 |
The 7 highest global ranking categories range from 91 (postoperative length of hospital stay > 90 days) to 97 (operative mortality). (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 103 |
| Placebo Arm | 122 |
(NCT03229538)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 12 |
| Placebo Arm | 17 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 31 |
| Placebo Arm | 24 |
"Based upon the STS-CHSD registry defined cardiac dysfunction resulting in low cardiac output complication variable." (NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 31 |
| Placebo Arm | 37 |
(NCT03229538)
Timeframe: Until hospital discharge, up to 4 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm | 41 |
| Placebo Arm | 51 |
The inotropic score was calculated by the equation using drug dosages in micrograms/kg/min, (dopamine+dobutamine) + (milrinonex10) + (epinephrinex100) and recorded hourly upon arrival to the ICUthrough 36 hours postoperatively. The highest score during this timeframe was recorded. This score converts dosages of commonly used inotropic medications into a score. The higher the score the more inotropic medications required. The minimum score would be zero indicating no inotropic medications were used. There is no maximum score. (NCT00934843)
Timeframe: over the first 36 hours after surgery
| Intervention | Scores on a scale (Mean) |
|---|---|
| MP Single Dose | 14.4 |
| MP Two Dose | 15.0 |
Number of participants who died of any cause between 36 hours and 30 days following cardiac surgery (NCT00934843)
Timeframe: at 36 hours and 30 days
| Intervention | participants (Number) |
|---|---|
| MP Single Dose | 1 |
| MP Two Dose | 0 |
The presence of low cardiac output syndrome (LCOS) was defined by the same definition used in the PRIMACORP study (Hoffman TM.et.al. Circulation 2003 107:996-1002). Specifically, if there were clinical signs and symptoms of low cardiac output (e.g., tachycardia, oliguria, cold extremities, cardiac arrest, etc.) which required one or more of the following interventions: mechanical circulatory support, the escalation of existing pharmacological circulatory support to >100% over baseline, or the initiation of new pharmacological circulatory support. (NCT00934843)
Timeframe: 36 hours
| Intervention | participants (Number) |
|---|---|
| MP Single Dose | 17 |
| MP Two Dose | 15 |
Total urine output in mL over the first 36 hours after cardiac surgery (NCT00934843)
Timeframe: over 36 hours
| Intervention | mL (Mean) |
|---|---|
| MP Single Dose | 498 |
| MP Two Dose | 453 |
Total amount of all fluids in and out during the first 36 hours postoperatively in mL. (NCT00934843)
Timeframe: over 36 hours
| Intervention | mL (Mean) | |
|---|---|---|
| Total Fluid in at 36 hr | Total Fluid out at 36 hr | |
| MP Single Dose | 575 | 600 |
| MP Two Dose | 586 | 558 |
4 reviews available for milrinone and Abnormality, Heart
| Article | Year |
|---|---|
Milrinone for the treatment of heart failure caused by severe Pneumonia in children with congenital heart disease: a meta-analysis.
Topics: Child; China; Heart Defects, Congenital; Heart Failure; Humans; Milrinone; Pneumonia | 2023 |
The Use of Cardiotonic Drugs in Neonates.
Topics: Adrenal Cortex Hormones; Asphyxia Neonatorum; Cardiotonic Agents; Dobutamine; Dopamine; Heart Defect | 2019 |
Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Topics: Cardiac Output, Low; Cardiotonic Agents; Dobutamine; Heart Defects, Congenital; Humans; Hydrazones; | 2015 |
The role of milrinone in children with cardiovascular compromise: review of the literature.
Topics: Administration, Inhalation; Adolescent; Cardiac Output, Low; Cardiotonic Agents; Child; Child, Presc | 2011 |
10 trials available for milrinone and Abnormality, Heart
| Article | Year |
|---|---|
Prevention of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery: A Double-Blind Randomized Clinical Pilot Study Comparing Dobutamine and Milrinone.
Topics: Adolescent; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Child; Child, Preschool | 2018 |
The Effect of Levosimendan Versus Milrinone on the Occurrence Rate of Acute Kidney Injury Following Congenital Heart Surgery in Infants: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Creati | 2019 |
Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Bl | 2014 |
Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension.
Topics: Administration, Inhalation; Child; Child, Preschool; Female; Heart Defects, Congenital; Humans; Hype | 2010 |
Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial.
Topics: Blood Pressure; Cardiac Surgical Procedures; Child, Preschool; Double-Blind Method; Heart Defects, C | 2011 |
Levosimendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study.
Topics: Analysis of Variance; Body Surface Area; Cardiac Output; Cardiac Output, Low; Cardiopulmonary Bypass | 2012 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease.
Topics: Blood Pressure; Cardiac Output, Low; Child; Child, Preschool; Double-Blind Method; Endpoint Determin | 2003 |
Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children.
Topics: Blood Pressure; Bronchodilator Agents; Carbon Dioxide; Cardiopulmonary Bypass; Cardiotonic Agents; C | 2004 |
Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery.
Topics: Cardiac Output, Low; Cardiotonic Agents; Heart Defects, Congenital; Hemodynamics; Humans; Infant, Ne | 1995 |
Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics.
Topics: Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agents; Child, Preschool; Double-Blind Meth | 2002 |
18 other studies available for milrinone and Abnormality, Heart
| Article | Year |
|---|---|
Impact of preoperative management with subatmospheric therapy using nitrogen in neonates with congenital heart disease.
Topics: Blood Circulation; Cardiac Output; Female; Heart Defects, Congenital; Humans; Infant, Newborn; Lung; | 2020 |
Another Outcome Lost to the Benefits of Levosimendan?
Topics: Acute Kidney Injury; Cardiotonic Agents; Heart Defects, Congenital; Humans; Milrinone; Simendan | 2019 |
Milrinone Acts as a Vasodilator But Not an Inotrope in Children After Cardiac Surgery-Insights From Wave Intensity Analysis.
Topics: Cardiac Surgical Procedures; Cardiotonic Agents; Echocardiography; Female; Heart Defects, Congenital | 2020 |
Circulating cyclic adenosine monophosphate concentrations in milrinone treated paediatric patients after congenital heart surgery.
Topics: Adenosine Monophosphate; Cardiac Output, Low; Cardiotonic Agents; Child; Heart Defects, Congenital; | 2021 |
An Empirically Derived Pediatric Cardiac Inotrope Score Associated With Pediatric Heart Surgery.
Topics: Age Factors; Bayes Theorem; Cardiac Surgical Procedures; Cardiotonic Agents; Child, Preschool; Clini | 2018 |
Bioactive Oxylipins in Infants and Children With Congenital Heart Disease Undergoing Pediatric Cardiopulmonary Bypass.
Topics: Biomarkers; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Child; Child, Preschool; Fatty Acid | 2020 |
Incidence of milrinone blood levels outside the therapeutic range and their relevance in children after cardiac surgery for congenital heart disease.
Topics: Cardiac Output; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Chromatogra | 2013 |
A neonate with critical congenital heart disease.
Topics: Adrenergic alpha-Agonists; Cardiopulmonary Resuscitation; Cardiotonic Agents; Critical Care; Dopamin | 2014 |
The Effect of Milrinone on Splanchnic and Cerebral Perfusion in Infants With Congenital Heart Disease Prior to Surgery: An Observational Study.
Topics: Blood Flow Velocity; Cardiac Output; Cardiotonic Agents; Celiac Artery; Cerebrovascular Circulation; | 2015 |
[Mulibrey syndrome: anesthetic management].
Topics: Abnormalities, Multiple; Anesthesia, Inhalation; Ascites; Child; Comorbidity; Dopamine; Drainage; Fe | 2010 |
Relation of milrinone after surgery for congenital heart disease to significant postoperative tachyarrhythmias.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cardiac Surgical Procedures; Child; Child, Preschool; Dose- | 2011 |
Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment.
Topics: Amiodarone; Cardiac Pacing, Artificial; Child; Child, Preschool; Dopamine; Female; Heart Defects, Co | 2002 |
Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease.
Topics: Cardiotonic Agents; Dobutamine; Female; Fontan Procedure; Heart Bypass, Right; Heart Defects, Congen | 2008 |
Pharmacologic support with high-energy phosphate preservation in the postischemic neonatal heart.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Animals, Newborn; Cardiotonic Agents; Cyclic A | 1995 |
Prolonged high frequency jet ventilation and milrinone therapy following modified Fontan procedure.
Topics: Cardiotonic Agents; Child; Heart Atria; Heart Defects, Congenital; High-Frequency Jet Ventilation; H | 1994 |
[Effects of milrinone in patients undergoing cardiac surgery].
Topics: Adult; Aged; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Arter | 1997 |
[Hemodynamic effects of amrinone or milrinone in infant after right heart bypass operation].
Topics: Amrinone; Child; Child, Preschool; Dopamine; Heart Bypass, Right; Heart Defects, Congenital; Hemodyn | 1998 |
The pharmacokinetics of milrinone in pediatric patients after cardiac surgery.
Topics: Body Weight; Heart Defects, Congenital; Hemodynamics; Humans; Infant; Milrinone; Models, Biological; | 1999 |